LIAISON®

murex Anti-HEV

DIAGNOSTIC SOLUTION

The combined testing solution for the detection of antibodies to Hepatitis E virus
LIAISON® murex Anti-HEV IgG & IgM

The first fully automated chemiluminescence immunoassays for the diagnosis of HEV infection and the selection of organ, tissue and cells post-mortem donors.

- Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide
- HEV infection is mostly asymptomatic and self-limiting but it can lead to fulminant hepatitis in pregnant women and patients with pre-existing liver disease
- The concentration of anti-HEV IgG antibodies could be useful in determining which level of IgG would be protective after natural infection or vaccine administration
- According to EASL guidelines, all patients with hepatitis should be tested for HEV, as part of the first-line virological investigation
- Most recent evidence on HEV transmission after transplantation suggests the need for a systematic screening of donors, particularly in endemic regions

Boost the global response to HEV with DiaSorin solution.
- Provide reliable results choosing the good performances of the LIAISON® murex HEV assays
- Enhance the diagnostic value of your results providing the quantification of IgG anti-HEV antibodies
- Be recognized as a reference Center for the organ donors selection by using the widest fully automated, chemiluminescent panel validated for the use on samples collected from dead donors
- Improve your capability to support the clinical patients management thank to the differentiation of five different viral hepatitis infections
- Improving the efficiency and the workflow of your laboratory through the consolidation on the LIAISON® XL platform of the widest automated menu for the diagnosis of Infectious Diseases and Viral Hepatitis

Clinical Performances:
- Anti-HEV IgM: 97.93% Specificity; 98.44% (PCR positive) Sensitivity
- Anti-HEV IgG: 99.22% Specificity; 97.92% Sensitivity

Expression of results:
- Anti-HEV IgG: quantitative (IU/mL)
- Anti-HEV IgM: qualitative (index)

Throughput:
- LIAISON® XL: 171 test/h
- LIAISON®, LIAISON® XS: 86 test/h

Time to first result: 35 minutes

Sample Type:
- Human Serum
- Human Plasma (Li-heparin, Na-heparin, K2-EDTA, K-oxalate, ACD, CPDA)

Reagent, Controls and Calibrators:
- Ready to use

Ordering Information

<table>
<thead>
<tr>
<th>Description</th>
<th>Kit configuration</th>
<th>Part number</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIAISON® Murex Anti-HEV IgG</td>
<td>100 tests</td>
<td>311270</td>
</tr>
<tr>
<td>LIAISON® Murex Control Anti-HEV IgG</td>
<td>2 levels/2 vial each</td>
<td>311271</td>
</tr>
<tr>
<td>LIAISON® Murex Anti-HEV IgM</td>
<td>100 tests</td>
<td>311280</td>
</tr>
<tr>
<td>LIAISON® Murex Control Anti-HEV IgM</td>
<td>2 levels/2 vial each</td>
<td>311281</td>
</tr>
</tbody>
</table>

References
1. Mehnaaz S Khuroo et al., J Viral Hepat. 2016 Feb;23(2):68-79
3. EASL Clinical Practice Guidelines on hepatitis E virus infection. 2018
4. Pourbaix A. et al., Transpl Infect Dis. 2017 Feb;19(1)

Available on LIAISON® systems
Product availability subject to required regulatory approval

DiaSorin S.p.A
Via Crescentino SNC, 13040 Saluggia (VC) - Italy
www.diasorin.com